Chimerix Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
04/08/2021 - 04:01 PM
DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021.
Details for the poster presentations are as follows:
ONC201: Characterization and combinatorial efficacy in brain tumors
Title: ADME and toxicology profiles of first-in-class DRD2/ClpP-targeted imipridone ONC201Abstract Number: 1370Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Sara Morrow, M.S., ChimerixSession Title: Pharmacology, Pharmacogenetics, and Pharmacogenomics
Title: Response to novel imipridone combination therapies targeting H3K27M mutant diffuse midline glioma (DMG)Abstract Number: 635Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Robyn Borsuk, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Pediatric Cancer: Clinical Investigations
Title: The integrated stress response (ISR) is involved in the synergistic combinatorial efficacy of ONC201 and epigenetic modulators in brain tumor cell linesAbstract Number: 1156Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Yiqun Zhang, Ph.D., Warren Alpert Medical School, Brown UniversitySession Title: HDAC and Methyltransferase Inhibitors
ONC201: Combinatorial efficacy in other solid tumors
Title: Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell deathAbstract Number: 1060Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Wen-I Chang, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Combination Therapies
Title: ONC201 as a novel anti-cancer therapeutic via modulation of inhibitors of apoptosis and up-regulation of DR5 in gastric adenocarcinomaAbstract Number: 1044Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Cassandra Parker, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Combination Therapies
Title: Imipridones exhibit synergy with sorafenib, HDAC inhibition, PARP inhibition, and proteasome inhibition in liver cancer cell linesAbstract Number: 1040Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Joshua Honeyman, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Combination Therapies
ONC206: Mechanism of action and biomarkers
Title: Predictive Biomarker Evaluation and Molecular Differentiation for Imipridones ONC201 and ONC206Abstract Number: 393Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Varun V. Prabhu, Ph.D., ChimerixSession Title: Biomarkers Predictive of Therapeutic Benefit
Title: Novel imipridone ONC206 suppresses ovarian cancer progression through modulating immune cell responseAbstract Number: 1440Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Chi-Lam Au-Yeung, Ph.D., MD Anderson Cancer CenterSession Title: Role of Microenvironment in therapeutic response
ONC212: Efficacy in pancreatic cancer
Title: Combination therapy with MEK inhibitors and a novel anti-neoplastic drug, imipridone ONC212, demonstrates synergy in pancreatic ductal adenocarcinoma cell linesAbstract Number: 1006Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Alexander G. Raufi, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Cellular Responses to Anticancer Drugs
Title: ONC212-induced impairment of oxidative phosphorylation is synergistic with glycolysis inhibition in treatment of pancreatic cancer in vitro and in vivoAbstract Number: 2329Date and Time: April 10, 2021 from 8:30 a.m. - 11:59 p.m. EDT Presenter: Anna Louie, M.D., Warren Alpert Medical School, Brown UniversitySession Title: Metabolic Pathways
Posters will be available for registered attendees on the AACR website on April 10, 2021.
About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.
CONTACT: Investor Relations: Michelle LaSpaluto 919 972-7115ir@chimerix.com
Will O’Connor Stern Investor Relations 212-362-1200will@sternir.com